Citius Oncology, Inc. (CTOR)

Market Cap	175.49M
Revenue (ttm)	n/a
Net Income (ttm)	-25.98M
Shares Out	85.19M
EPS (ttm)	-0.37
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	199,383
Open	2.060
Previous Close	2.060
Day's Range	2.050 - 2.120
52-Week Range	0.551 - 49.000
Beta	3.01
Analysts	Buy
Price Target	6.00 (+191.26%)
Earnings Date	Aug 15, 2025

About CTOR

Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2021
• Country: United States
• Stock Exchange: NASDAQ
• Ticker Symbol: CTOR

Financial Performance

Financial numbers in USD

Analyst Summary

According to 2 analysts, the average rating for CTOR stock is "Buy." The 12-month stock price target is $6.0, which is an increase of 191.26% from the latest price.

Price Target

$6.0

(191.26% upside)

Analyst Consensus: Buy